Literature DB >> 26989104

Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics.

Samiksha Ghimire1, Mathieu S Bolhuis1, Marieke G G Sturkenboom1, Onno W Akkerman2, Wiel C M de Lange2, Tjip S van der Werf3, Jan-Willem C Alffenaar4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26989104     DOI： 10.1183/13993003.00040-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  18 in total

1.  Membrane Filtration Is Suitable for Reliable Elimination of Mycobacterium tuberculosis from Saliva for Therapeutic Drug Monitoring.

Authors:  Simone H J van den Elsen; Tridia van der Laan; Onno W Akkerman; Adri G M van der Zanden; Jan-Willem C Alffenaar; Dick van Soolingen
Journal:  J Clin Microbiol       Date:  2017-08-09       Impact factor: 5.948

2.  Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

Authors:  Jan-Willem C Alffenaar; Simon Tiberi; Roger K Verbeeck; Scott K Heysell; Martin P Grobusch
Journal:  Clin Infect Dis       Date:  2016-10-06       Impact factor: 9.079

3.  Pharmacokinetics of tuberculosis drugs in HIV-infected patients from Irkutsk, Russian Federation: redefining drug activity.

Authors:  Galina Lyles; Oleg Ogarkov; Svetlana Zhdanova; Charles A Peloquin; Andrew Ebers; Herman Pfaeffle; Mohammad H Al-Shaer; Elena Moiseeva; Elena Zorkaltseva; Mikhail Koscheev; Eric R Houpt; Scott K Heysell
Journal:  Eur Respir J       Date:  2018-05-24       Impact factor: 16.671

4.  Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.

Authors:  Samiksha Ghimire; Bhagwan Maharjan; Erwin M Jongedijk; Jos G W Kosterink; Gokarna R Ghimire; Daan J Touw; Tjip S van der Werf; Bhabana Shrestha; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

5.  Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis.

Authors:  Reihaneh Abolhassani-Chimeh; Onno W Akkerman; Antonia M I Saktiawati; Nieko C Punt; Mathieu S Bolhuis; Yanri W Subronto; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar; Marieke G G Sturkenboom
Journal:  Antimicrob Agents Chemother       Date:  2022-06-21       Impact factor: 5.938

6.  Clinical standards for drug-susceptible pulmonary TB.

Authors:  O W Akkerman; R Duarte; S Tiberi; H S Schaaf; C Lange; J W C Alffenaar; J Denholm; A C C Carvalho; M S Bolhuis; S Borisov; J Bruchfeld; A M Cabibbe; J A Caminero; I Carvalho; J Chakaya; R Centis; M P Dalcomo; L D Ambrosio; M Dedicoat; K Dheda; K E Dooley; J Furin; J-M García-García; N A H van Hest; B C de Jong; X Kurhasani; A G Märtson; S Mpagama; M Munoz Torrico; E Nunes; C W M Ong; D J Palmero; R Ruslami; A M I Saktiawati; C Semuto; D R Silva; R Singla; I Solovic; S Srivastava; J E M de Steenwinkel; A Story; M G G Sturkenboom; M Tadolini; Z F Udwadia; A R Verhage; J P Zellweger; G B Migliori
Journal:  Int J Tuberc Lung Dis       Date:  2022-07-01       Impact factor: 3.427

Review 7.  Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.

Authors:  Johanna Kuhlin; Marieke G G Sturkenboom; Samiksha Ghimire; Ioana Margineanu; Simone H J van den Elsen; Noviana Simbar; Onno W Akkerman; Erwin M Jongedijk; Remco A Koster; Judith Bruchfeld; Daan J Touw; Jan-Willem C Alffenaar
Journal:  Clin Mass Spectrom       Date:  2018-10-19

8.  Therapeutic Drug Monitoring of Anti-infective Drugs: Implementation Strategies for 3 Different Scenarios.

Authors:  Hannah Yejin Kim; Kenneth C Byashalira; Scott K Heysell; Anne-Grete Märtson; Stellah G Mpagama; Prakruti Rao; Marieke G G Sturkenboom; Jan-Willem C Alffenaar
Journal:  Ther Drug Monit       Date:  2022-02-01       Impact factor: 3.118

9.  Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study.

Authors:  Daan J Touw; Giovanni B Migliori; Jan-Willem Alffenaar; Simone Hj van den Elsen; Marieke Gg Sturkenboom; Onno Akkerman; Linda Barkane; Judith Bruchfeld; Geoffrey Eather; Scott K Heysell; Henadz Hurevich; Liga Kuksa; Heinke Kunst; Johanna Kuhlin; Katerina Manika; Charalampos Moschos; Stellah G Mpagama; Marcela Muñoz Torrico; Alena Skrahina; Giovanni Sotgiu; Marina Tadolini; Simon Tiberi; Francesca Volpato; Tjip S van der Werf; Malcolm R Wilson; Joaquin Zúñiga
Journal:  BMJ Open       Date:  2020-06-16       Impact factor: 2.692

10.  Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.

Authors:  Onno W Akkerman; Floris Grasmeijer; Wiel C M de Lange; Huib A M Kerstjens; Gerard de Vries; Mathieu S Bolhuis; Jan-Willem Alffenaar; Henderik W Frijlink; Grace Smith; Roger Gajraj; Rina de Zwaan; Paul Hagedoorn; Martin Dedicoat; Dick van Soolingen; Tjip S van der Werf
Journal:  Eur Respir J       Date:  2018-03-22       Impact factor: 16.671
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.